Positives:
- organic growth of 9.7% is good
- looks like Vlad is attempting to get Hills/DAS back on track with profit expected from 2Q
- 1Q is generally the slowest with 2Q (tax/EOFY sales) and 4Q generally stronger so lets hope that remains the case
- gross margins improved on 2H despite higher interest rates so perhaps it does seem like the underlying business profitability is improving
Negatives
- Pbt margin still only 3.4% which is an improvement on 2H22, but still a long way from ~4% achieved before Exeed purchase (NZ margins have always been lower than Australia, but the Exeed purchase seems to be the tail wagging the dog.....the preso for FY22 indicated a retail presence and I wonder if that is what is hurting the entire business)
The lower quarterly dividend I hope signals a conservative approach rather than some indication of a slowdown (backorders have come down from 3Q last year so perhaps that leaves some uncertainty to a strong year?).
- Forums
- ASX - By Stock
- Ann: Q1 FY23 Market Update
DDR
dicker data limited
Add to My Watchlist
0.36%
!
$8.35

Positives: - organic growth of 9.7% is good - looks like Vlad is...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$8.35 |
Change
-0.030(0.36%) |
Mkt cap ! $1.508B |
Open | High | Low | Value | Volume |
$8.40 | $8.54 | $8.34 | $3.818M | 453.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1654 | $8.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$8.37 | 9081 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1654 | 8.350 |
2 | 1404 | 8.340 |
2 | 3600 | 8.320 |
1 | 1200 | 8.280 |
1 | 3026 | 8.260 |
Price($) | Vol. | No. |
---|---|---|
8.370 | 9081 | 1 |
8.420 | 1 | 1 |
8.450 | 5 | 1 |
8.500 | 232 | 1 |
8.550 | 120 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
DDR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online